Results 1 to 10 of about 94,931 (305)
Some of the next articles are maybe not open access.

Mitomycin C in Photorefractive Keratectomy

Journal of Refractive Surgery, 2009
Purpose: To evaluate the outcome of primary or retreatment photorefractive keratectomy (PRK) or photo-therapeutic keratectomy (PTK) with mitomycin C (MMC) 0.02% applied prophylactically intraoperatively for the prevention of haze and regression in cases of significant haze and regression after primary PRK, due to previous ...
Ashraf, Shalaby   +2 more
openaire   +2 more sources

Pharmacokinetics of intraperitoneal mitomycin C

Surgical Oncology Clinics of North America, 2003
The favorable pharmacokinetics of MMC, used during intraperitoneal chemotherapy, has been reported in several studies [11-19]. A major safety issue in studies using intraperitoneal chemotherapy perfusion is the resulting systemic drug exposure. The AUCplasma is determined by the dose, the clearance, and the fraction absorbed from the peritoneal cavity.
S, van Ruth   +2 more
openaire   +2 more sources

Intraoperative Mitomycin C in Dacryocystorhinostomy

Ophthalmic Plastic and Reconstructive Surgery, 2001
To assess the efficacy of intraoperative mitomycin C (MMC) in external dacryocystorhinostomy (EXT-DCR).Forty-six cases (50 lacrimal drainage systems [LDS]) with nasolacrimal duct obstruction were randomized into three groups. In the control group, a standard EXT-DCR procedure was performed. In the two MMC groups, a piece of cotton soaked with 0.2 mg/ml
Y A, You, C T, Fang
openaire   +2 more sources

Reductive activation of mitomycin C

Biochemistry, 1988
Mitomycin C, an antitumor antibiotic, is known to require reductive activation in order to function as an alkylating agent. In this work reduction has been carried out by using radiolytically produced formate radicals that reduce mitomycin C to its semiquinone in a clean rapid one-electron reaction.
B M, Hoey, J, Butler, A J, Swallow
openaire   +2 more sources

Current treatment and future directions in the management of anal cancer

Ca-A Cancer Journal for Clinicians, 2022
Leila T Tchelebi   +2 more
exaly  

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer

Signal Transduction and Targeted Therapy, 2020
Shao-Cong Wu, Liwu Fu
exaly  

Mitomycin C

1987
Jos H. Beijnen   +2 more
openaire   +1 more source

Mitomycin C

2015
Marko Ostovic, Thomas Kohnen
openaire   +2 more sources

Home - About - Disclaimer - Privacy